Glucagon Like Peptide 1 Receptor Agonists for Targeted Delivery of Antisense Oligonucleotides to Pancreatic Beta Cell

Laurent Knerr(AstraZeneca (Sweden)), Shalini Andersson(AstraZeneca (Sweden)), Eric Valeur(AstraZeneca (Sweden)), Leonardo De Maria(Novozymes (Denmark)), Elaine Pirie(Ionis Pharmaceuticals (United States)), Michael E. Østergaard(Ionis Pharmaceuticals (United States)), Johan Broddefalk(AstraZeneca (Sweden)), Linda Sundström(AstraZeneca (Sweden)), Rasmus Jansson‐Löfmark(AstraZeneca (Sweden)), Carina Ämmälä(AstraZeneca (Sweden)), Johan Meuller(AstraZeneca (Sweden)), Wuxia Fu(Ionis Pharmaceuticals (United States)), Maria Ölwegård-Halvarsson(AstraZeneca (Sweden)), Ahlke Hayen(AstraZeneca (Sweden)), Patrik Andersson(Karolinska Institutet), Punit P. Seth(Ionis Pharmaceuticals (United States)), Mehran Nikan(Ionis Pharmaceuticals (United States)), Thazha P. Prakash(Ionis Pharmaceuticals (United States)), William J. Drury(Ionis Pharmaceuticals (United States)), Richard Lee(Ionis Pharmaceuticals (United States)), David Janzén(AstraZeneca (Sweden))
Journal of the American Chemical Society
February 24, 2021
Cited by 72


Related Papers